newsfilter
← Earnings
Earnings Releases·

Wave Life Sciences — Third Quarter 2026 Earnings Summary

  • Revenue increased to $13.2 million in Q3 2026 from $7.6 million in the prior year period, while net loss widened to $61.9 million from $53.9 million due to higher R&D ($53.8M vs $45.9M) and G&A ($25.4M vs $18.1M) expenses.
  • The company maintains a cash runway into Q3 2028 with $431.0 million in liquid assets and expects a $12 million GSK milestone payment in Q4 2026.
  • Clinical progress includes ongoing Phase 2a dosing for WVE-007, a Q4 2026 CTA filing for WVE-008, and planning for a registrational trial for WVE-006 following positive FDA feedback.
  • Strategic updates include the appointment of Monika Vnuk as Chief Business Officer and the selection of a SpiNA design candidate by GSK for a hepatology indication, with potential milestones up to $375 million per program.
Company
WAVE LIFE SCIENCES INC
Sector
Healthcare
Industry
Biotechnology